Comparative Pharmacology
Head-to-head clinical analysis: ASMANEX HFA versus NAFAZAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ASMANEX HFA versus NAFAZAIR.
ASMANEX HFA vs NAFAZAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Mometasone furoate is a corticosteroid that exerts anti-inflammatory effects by inhibiting multiple inflammatory cell types and mediators, including eosinophils, mast cells, macrophages, and lymphocytes, and reducing the release of pro-inflammatory cytokines and chemokines.
Unknown. It is a purified fatty acid derivative that may modulate inflammatory responses.
2 inhalations (100 mcg each) twice daily orally, maximum 400 mcg/day.
2.5 mg subcutaneously once daily.
None Documented
None Documented
The terminal elimination half-life of mometasone furoate following inhalation is approximately 25 hours (range 15–40 hours), reflecting slow absorption from the lungs and prolonged systemic clearance.
Terminal elimination half-life is 6-8 hours; in moderate renal impairment (CrCl 30-50 mL/min) extends to 12-15 hours.
Following oral inhalation, the absorbed fraction of mometasone furoate is extensively metabolized in the liver. Excretion is primarily via feces (approximately 74%) and urine (approximately 8%) as metabolites. Biliary excretion contributes to fecal elimination.
Primarily renal excretion (70-80% as unchanged drug), with 15-20% fecal elimination via biliary secretion.
Category C
Category C
Corticosteroid, Inhaled
Intranasal Antihistamine/Corticosteroid